A systematic review of pharmacogenetic testing to guide antipsychotic treatment
Noushin Saadullah Khani, Georgie Hudson, Georgina Mills, Soumita Ramesh, Lauren Varney, Marius Cotic, Rosemary Abidoph, Alvin Richards‐Belle, Lorena Carrascal-Laso, Manuel Franco, Benjamin Skov Kaas‐Hansen, Gesche Jűrgens, Barbara Barrett, Huajie Jin, Elvira Bramon
Abstract
Pharmacogenomics could optimize antipsychotic treatment by preventing adverse drug reactions, improving treatment efficacy or relieving the cost burden on the healthcare system. Here we conducted a systematic review to investigate whether pharmacogenetic testing in individuals undergoing antipsychotic treatment influences clinical or economic outcomes. On 12 January 2024, we searched MEDLINE, EMBASE, PsycINFO and Cochrane Centrale Register of Controlled Trials. The results were summarized using a narrative approach and summary tables. In total, 13 studies were eligible for inclusion in the systematic review. The current evidence base is either in favor of pharmacogenetics-guided prescribing or showed no difference between pharmacogenetics and treatment as usual for clinical and economic outcomes. In the future, we require randomized controlled trials with sufficient sample sizes that provide recommendations for patients who take antipsychotics based on a broad, multigene panel, with consistent and comparable clinical outcomes.